Introduction of Hypermatrix and Operator Notation into a Discrete Mathematics Simulation Model of Malignant Tumour Response to Therapeutic Schemes In Vivo. Some Operator Properties by Stamatakos, Georgios S. & Dionysiou, Dimitra D.
Cancer Informatics 2009:7 239–251
This article is available from http://www.la-press.com.
© the authors, licensee Libertas Academica Ltd.
This is an open access article distributed under the terms of the Creative Commons Attribution License  
(http://www.creativecommons.org/licenses/by/2.0) which permits unrestricted use, distribution and reproduction  
provided the original work is properly cited.
Cancer Informatics 2009:7  239
Open Access
Full open access to this and 
thousands of other papers at 
http://www.la-press.com.
Cancer Informatics
O r I g I n A L   r e s e A r C h
Introduction of Hypermatrix and Operator notation 
into a Discrete Mathematics simulation Model of Malignant 
Tumour Response to Therapeutic schemes In Vivo. some 
Operator properties
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In Silico Oncology group, Laboratory of Microwaves and Fibre Optics, Institute of Communication and Computer systems, 
school of electrical and Computer engineering, national Technical University of Athens, gr-157 80 Zografos, greece.
Abstract: The tremendous rate of accumulation of experimental and clinical knowledge pertaining to cancer dictates the development 
of a theoretical framework for the meaningful integration of such knowledge at all levels of biocomplexity. In this context our research 
group has developed and partly validated a number of spatiotemporal simulation models of in vivo tumour growth and in particular 
tumour response to several therapeutic schemes. Most of the modeling modules have been based on discrete mathematics and therefore 
have been formulated in terms of rather complex algorithms (e.g. in pseudocode and actual computer code). However, such lengthy 
algorithmic descriptions, although sufficient from the mathematical point of view, may render it difficult for an interested reader to 
readily identify the sequence of the very basic simulation operations that lie at the heart of the entire model. In order to both alleviate 
this problem and at the same time provide a bridge to symbolic mathematics, we propose the introduction of the notion of hypermatrix 
in conjunction with that of a discrete operator into the already developed models. Using a radiotherapy response simulation example 
we demonstrate how the entire model can be considered as the sequential application of a number of discrete operators to a hypermatrix 
corresponding to the dynamics of the anatomic area of interest. Subsequently, we investigate the operators’ commutativity and outline 
the “summarize and jump” strategy aiming at efficiently and realistically address multilevel biological problems such as cancer. In order 
to clarify the actual effect of the composite discrete operator we present further simulation results which are in agreement with the 
outcome of the clinical study RTOG 83–02, thus strengthening the reliability of the model developed.
Keywords: cancer multiscale modeling, computer models, in silico oncology, tumour growth, tumour response to treatment, oncosim­
ulator, radiobiology, operator notation, hypermatrixstamatakos and Dionysiou
240  Cancer Informatics 2009:7
1. Introduction
An inelastic prerequisite for an effective treatment 
of cancer is understanding and modeling the corres­
ponding  spatiotemporal  natural  phenomenon  of 
tumour growth and response to therapeutic schemes 
concurrently  on  several  biocomplexity  levels.  The 
usually fast growth and resilience of tumours suggest 
that they are emerging, opportunistic systems rather 
than random, disorganized and diffuse cell masses.1,2 
Therefore, the entire in vivo growing tumour rather 
than only a single cell3 must be investigated and treated 
as a self­organizing complex dynamic system. In this 
context  there  is  need  for  advanced  computational 
models to simulate the complexity of solid tumour 
growth, invasion and metastasis combining a range 
of disciplines including medical, biological, biophy­
sical, engineering and statistical physics research.4
This section provides a brief outline of several 
of the concepts and earlier research efforts to model 
tumour  behaviour.  Duechting  et  al5  introduced  a 
simulation model which concerns the in vitro case 
or the early avascular stages of small in vivo tumours 
and is based on a consideration of the distinct phases 
of the cell cycle. Kocher et al6,7 presented a simula­
tion model of the development of a tumour spheroid 
and its response to radiosurgery. The detailed imaging 
based geometry of the clinical tumour which might 
facilitate the direct clinical validation of the model 
had not been considered however. Instead an equiva­
lent spherical tumour was considered in place of the 
generally arbitrarily shaped actual tumour. Addition­
ally, detailed cell cycle phase biology (phases G1, S, 
G2, M) had not been taken into account, grouping of 
the cells into only proliferating and dormant classes 
being considered instead. It is noted that none of the 
above mentioned models has been applied to large 
clinical tumours (of varied geometrical shapes) and 
none of them simulates shrinkage for an arbitrarily 
shaped clinical tumour undergoing treatment. In the 
pure  tumour  growth  models  presented  by  Kansal 
et al1,2 a discretising grid is used in which each 
geometrical cell is able to contain a large number 
of biological cells, although the grid has not been 
used to discretise clinical tumours of arbitrary shape. 
Swanson  et  al,8,9  Mandonnet  et  al,10  have  devel­
oped  clinically  oriented  spatiotemporally  models 
of  tumour  growth  and  invasion  concerning  glio­
blastoma multiforme (GBM). Although growth and 
invasion constitute fundamental phenomena related 
to  GBM  treatment  optimization,  the  investigators 
have not focused neither on the radiobiological nor 
on the pharmacodynamic mechanisms that determine 
the  cell  survival  probabilities  and  the  subsequent 
shrinkage. Byrne et al11 and Alarcon et al,12–14 have 
developed mathematical models of avascular tumour 
growth and angiogenesis evolution pertinent mainly 
to the initial stages of tumour development. Valuable 
insight can be gained using such models, but exten­
sion to clinical voluminous tumours is not an a priori 
manageable task. Wise et al15 have developed a three 
dimensional multi­species non linear tumour growth 
model. A review of significant efforts to model cancer 
in silico (=on the computer) has also been presented 
by Deisboeck et al.16
An effort to overcome some of the above men­
tioned limitations has been previously made by our 
research  group  through  the  development  of  four­
dimensional  patient-specific  in  vivo  simulation 
models of imageable tumour response to radiothera­
peutic and chemotherapeutic schemes.17–29 All param­
eters used in the models have already been defined 
and can be determined (in principle) experimentally 
or clinically. Therefore, use of new mathematically 
dictated parameters of ambiguous physical meaning 
has been avoided.
Looking  now  at  the  problem  of  cancer  from  a 
broader  theoretical  perspective  we  realize  that  the 
impressive  rate  of  production  of  experimental  and 
clinical knowledge pertaining to the disease dictates 
the development of a generic and desirably universal 
theoretical  framework  for  the  meaningful  integra­
tion  of  such  knowledge.  The  obvious  reasons  for 
knowledge integration are both deeper understand­
ing of cancer and optimization of therapeutic schemes 
on the patient individualized context by performing 
in  silico  experiments. At  the  same  time  as  cancer 
is  an  excellent  paradigm  of  multilevel  biological 
phenomena  any  rigorous  theoretical  treatment  of 
cancer dynamics could provide important hints for 
the  modeling  and  simulation  of  other  biological 
phenomena including other homeostatic imbalances 
(diseases).22 Αs more and more complexity aspects of 
the natural phenomenon of cancer are incorporated 
into mathematical and computational models impor­
tant discrete mathematics modeling treatments tend 
to become difficult to understand by the wider cancer Introduction of hypermatrix and operator notation into a discrete mathematics 
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modeling  community.  Therefore,  the  need  for  a 
symbolic mathematical notation has become obvious. 
Such an approach could be viewed as following the 
formalist school founded by D. Hilbert.30 According 
to the formalist thesis mathematics is concerned with 
formal symbolic systems.
Stimulated  by  these  remarks  we  present  the 
introduction of an operator notation into the malig­
nant tumour response to therapeutic schemes in vivo 
making  use  of  several  versions  of  the  simulation 
model developed by our group (see citations above). 
In order to proceed to the introduction of a discrete 
mathematics  operator  notation  the  anatomic  region 
of  interest  and  its  biological  dynamics  are  repre­
sented  by  a  hypermatrix  α. A  hypermatrix  can  be 
viewed as a matrix of  [a matrix of [… of  [matrices 
(or vectors) ]…]]. The hypermatrix α is created by the 
superposition of a discretization mesh on the anatomic 
region of interest and the consideration of equivalence 
classes within each geometrical cell of the mesh rep­
resenting the various phases within or out of the cell 
cycle that a biological cell can be found. Discrete time 
represents a further dimension of the hypermatrix.
2. Discretization of the Biological 
problem
Collection of the appropriate imaging data (e.g. MRI 
T1 contrast enhanced, CT/PET, etc.), registration, inter­
polation and three dimensional reconstruction consti­
tute the initial steps of an in vivo discrete mathematics 
treatment of the tumour growth and therapy response 
phenomenon. A  discretizing  mesh  is  superimposed 
on the anatomic region of interest and the contents 
of each geometrical cell of the mesh are distributed 
into equivalence classes corresponding to the various 
phases within or out of cell cycle. The mean time spent 
within each phase is another parameter that charac­
terizes the subsets of each geometrical cell.18,23,24
3. Operator and Hypermatrix notation
The following mathematical entities are considered 
in the proposed treatment:  a stands for the hyper­
matrix  corresponding  to  and  dynamically  describ­
ing the anatomical region of interest (including the 
tumour and possibly the surrounding normal tissue). 
Each vector element of the hypermatrix α  is consid­
ered to have the following form that corresponds to a 
discretization mesh geometrical cell:
  a x y z p t g N t h h i j k l n
ijkln
p
ijkln
p
ijkln
p
ijkln
p
ijkln ( , , , , ) , , , , = (  ) )
  (1)
a t a ( ) 0 0 =  initial state of the tumour (just before the 
start of the treatment course to be simulated) 
(2)
where the following symbols have been introduced:
p: phase within or out of the cell cycle
g: oxygen and nutrient provision
Np: number of biological cells in phase p
tp: mean time spent in phase p (time is usually mea­
sured in h)
hp: number of therapy hit cells residing in phase p
 hp  number  of  non  therapy  hit  cells  residing  in 
phase p
  xi ∈ [xmin, xmax]  (3)
  yj ∈ [ ymin, ymax]  (4)
  zk ∈ [zmin, zmax]  (5)
  tn ∈ [0, tmax]  (6)
  pl ∈ [G1, S, G2, M, G0, A, N, D]  (7)
where
ξmin,ξmax denote the minimum and maximum value 
respectively  of  the  generic  variable  ξ  during  the 
simulation
G1 denotes the G1 cell cycle phase,
S denotes the DNA synthesis phase,
G2 denotes the G2 cell cycle phase,
M denotes mitosis,
G0 denotes the dormant G0 phase,
A denotes the apoptotic phase,
N denotes the necrotic phase,
D denotes the remnants of dead cells,
  g s s ∈{ , }    (8)
s stands for suffcient oxygen and nutrient provision 
(for  tumour  cell  proliferation),   s  stands  for  insuff­
cient  oxygen  and  nutrient  provision  (for  tumour  cell 
proliferation).
Obviously  this  binary  character  of  the  oxygen 
and nutrient provision is to be considered only a first 
simplifying approximation.
  Np∈N0  (9)stamatakos and Dionysiou
242  Cancer Informatics 2009:7
N0 is the set of non negative integers
  tp∈[0,tp max]  (11)
  hp∈[0, Np]  (12)
   h N p P ∈[ , ] 0   (13)
It should be noted that in general all physicobio­
logically different components of each hypermatrix 
element  can  be  considered  dependent  on  all  five 
dimensions of the proposed abstract space of tumour 
dynamics. For example oxygen and nutrient provision 
can change dramatically in space and time within the 
tumour. The treatment outcome is generally depen­
dent on the phase in which a cell resides when irradi­
ated or treated with chemotherapy. Cell cycle phases 
have generally different durations and therefore the 
mean time spent within each phase equivalence class 
of a given geometrical cell is dependent on the cell 
phase. Even the oxygen and nutrient provision (to the 
biological cells belonging to the same phase within 
a geometrical cell) may be microscopically related 
to the phase under consideration. A relatively large 
number of tumour cells within the G0 phase located 
around a given point may imply inadequate oxygen 
and nutrient provision, although in this particular case 
dormancy is normally the outcome rather than the 
cause of inadequate oxygen and nutrient provision
Figure 1 provides a schematic representation of 
the proposed five dimensional discrete abstract space 
of tumour dynamics. Three dimensions (those corre­
sponding to the variables xi, yj, zk) represent space, 
another one (corresponding to the variable tn) time and 
the fifth one (corresponding to the variable pl) repre­
sents the cell phase within or out of the cell cycle in 
which a biological cell or a set of cells within a geo­
metrical cell of the discretization mesh is found at a 
given instant. The entire simulation can be viewed as 
the periodic application of a number of discrete algo­
rithmic operators on the hypermatrix of the anatomic 
region of interest. The period of application is equal 
to the time separating two consecutive discretization 
mesh scans. This has been taken equal to 1h in all 
applications referred to in this particular paper.
The various modules of algorithmic manipulations 
on the hypermatrix can be thought of as correspond­
ing to discrete operators acting on the hypermatrix in 
analogy to the action of continuous operators on a wave 
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Figure 1. A schematic representation of equation 1 showing the location 
of an indicative hypermatrix element  a  (xi, yj, zk, pl, tn) and its physically 
inhomogeneous and multidimensional content  g N t h h
ijkln
p
ijkln
p
ijkln
p
ijkln
p
ijkln , , , ,  ( ) 
[see text for symbols;   h h G G 2 2 ≡ ]. The proposed five dimensional discrete 
abstract space of tumour dynamics (corresponding to the localization of 
each hypermatrix element) is shown on the bottom right of the diagram. 
Three dimensions (corresponding to variables xi, yj, zk) represent space, 
another one (corresponding to variable tn) represents time and the fifth 
one (corresponding to variable pl ) represents the cell phase within or out 
of the cell cycle in which a biological cell or a set of biological cells within 
a geometrical cell of the discretization mesh is found at a given instant.
function in quantum mechanics (Schiff  31 pp. 148–186). 
The critical importance of considering abstract (vector) 
spaces and operators has been made clear by practi­
cally  all  fields  of  physics  (Morse  and  Feshbach,32 
Part 1, pp. 76–92).Introduction of hypermatrix and operator notation into a discrete mathematics 
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In order to proceed to a symbolic formulation of 
the operator application we make use of the following 
symbols:
f stands for the composite discrete operator i.e. the 
operator formed by the synthesis of all partial opera­
tors sequentially acting on the hypermatrix. There­
fore, the updated hypermatrix at the time point tn+1 is 
given by
    (14)
The composite operator can be written as
  f = f  U f  E f  C f  H f  O f   T  (15)
where
 f   J, J ∈{U, E, C, H, O, T } stands for a “partial operator”
  (16)
T stands for time update (i.e. just the increase of time 
by e.g. 1 h and not the updated state of the hyperma­
trix α  at any time tn).
O stands for the oxygen and nutrient provision status
H stands for the effect of therapy (mainly cell survival)
C stands for the eventually perturbed cell cycling due 
to therapy
E stands for differential expansion or shrinkage
U stands for oxygen and nutrients field update
  f f f f f f a t
a t n
U E C H O T
n
n
( ( ( ( ( ( ))))))
= ( ) = +1 0 1 , , ,.....   (17)
or in a more compact writing:
 
f f f f f f a t
a t n
U E C H O T
n
n
( )
= ( ) = +1 0 1 , , ,.....  (18)
where  the  application  of  the  operators  takes  place 
from the right to the left.
It is noted that the term partial operator as used in 
this work essentially denotes the application of complex 
algorithmic manipulations. The entire model has been 
constructed with a number of algorithmic manipulations 
( partial operators) applied repeatedly in a given order. 
Therefore, the whole model (entire algorithm) can be 
considered as the application of a composite operator. 
Subsequently this composite operator can always be 
decomposed into partial operators since the former is 
nothing more than a conceptual clustering of the latter.
It  is  quite  obvious  that  the  above  mentioned 
concepts and symbols cannot include all the informa­
tion needed for the simulation to run. Their role is 
(at least at the present stage) rather to identify and 
decompose the major conceptual mathematical treat­
ment steps than to represent any assumption details. 
The proposed approach is to be seen as a continually 
evolving and optimized process. Examples of such 
evolutionary stages could be the following. In order 
to address the non imageable components of highly 
invasive  tumours  such  as  glioblastoma  multiforme 
at a large time scale further operators could be pro­
posed so as to explicitly handle diffusion phenomena 
at the cellular/tissue level. Additional operators could 
handle the refined biomechanics of the tumour and 
adjacent normal tissues as well complex molecular 
networks which largely determine the response of a 
single tumour cell to treatment (see Section 5).
4. non commutativity of the Operators
A careful study of the behaviour of any two of the 
“partial operators” f  J, f  K where J, K ∈ {U, E, C, H, O, T } 
reveals  that  they  are  non  commutative.  It  is  noted 
that the terms commutative and permutable are used 
interchangeably when applied to operators (but not 
always when applied to subgroups).33 For example 
applying the cell cycle clock (  f  C ) to the proliferating 
cells first and subsequently calculating the effect of 
a radiotherapy fraction (  f  H ) may lead to a substan­
tially larger number of surviving cells than the oppo­
site sequence. The reason for such a difference could 
be the successful completion of mitosis for far more 
tumor cells in the first case which would lead to a 
larger number of tumour cells (tumour burden) before 
treatment is applied. Furthermore, it must be stressed 
that in general each partial operator has to be applied 
concurrently on all elements­geometrical cells of the 
hypermatrix α  (possibly already transformed by other 
partial operators) as there are in general interdepen­
dences among the various geometrical cells [e.g. dif­
ferential shifting of the overflowing biological cells 
that have emerged following mitoses].
5. Multilevel Biology considerations: 
The “summarize and Jump” strategy
In  order  to  achieve  a  quite  realistic  prediction  of 
the response of a tumour to therapeutic interventions 
several levels of biocomplexity have to be addressed 
f a t a t n n ( ) ( )= ( ) +1stamatakos and Dionysiou
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at the same time. The decomposition of the composite 
discrete operator f to its constituent “partial opera­
tors” f  J, J ∈{U, E, C, H, O, T} provides a concep­
tual tool useful for the analysis and superposition 
of several critical mechanisms that may take place 
on different biocomplexity levels. For example the 
molecular profile of a given tumour (e.g. the expres­
sions of a number of critical genes) can be used in 
order to perturb the population based average sur­
vival fraction following irradiation with dose D so 
that  the  genetically  produced  radiosensitivity  or 
radioresistance of the particular tumour of a given 
patient is taken into account during the simulation. 
This “summary” of the molecular level phenomena 
is currently incorporated into the partial operator f  H 
which represents the microscopic effect of the treat­
ment intervention on the tumour. One could inter­
pret the procedure of perturbing the population based 
average values of the tumour biological parameters 
as a two step process. The first step refers to “sum­
marizing” what is happening on one biocomplexity 
level (here the molecular level) and providing the 
amount  of  perturbation  whereas  the  second  one 
refers to the “jumping” to another level (here the 
cellular level). In this case the “summary” refers to 
the percentage by which the survival fraction will 
have to be perturbed whereas the “jumping” refers 
to the fact that the individualized survival fraction is 
related to the cellular level on which the main bulk 
of the simulation process takes place. Furthermore, 
it is worth noting that it is at the cellular level that 
complete success or failure of tumour treatment is 
defined since complete success of tumour treatment 
implies that not even a single proliferative or dormant 
tumour cell has been left alive.
6. some Indicative points of the Model 
and their Correspondence to Specific 
“partial Operators”
The  introduction  of  the  suggested  notation  is 
demonstrated through a version of a simulation model 
of (T1 gadolinium enhanced ) imageable glioblastoma 
response to radiotherapeutic schemes. As a thorough 
account of the assumptions made would be beyond 
the scope of the present paper we only provide an 
indication  of  the  operator  notation  introduction 
by  referring  to  selected  modeling  points.  Further 
modeling details can be found i.a. in.18,19,23,24,26,27
In order to clinically validate the simulation model, 
a series of simulation executions corresponding to the 
various arms of the RTOG study 83­02 have been per­
formed.34 This was a randomized Phase I/II study of 
escalating doses for Hyperfractionated radiotherapy 
(HF, 1.2 Gy twice daily to doses of 64.8, 72, 76.8, 
or 81.6 Gy) and Accelerated Hyperfractionated radio­
therapy (AHF, 1.6 Gy twice daily to doses of 48 or 
54.4 Gy) with carmustine (BCNU) for adults with 
supratentorial  glioblastoma  multiforme  (GBM)  or 
anaplastic astrocytoma. The study has revealed that 
GBM patients who received the higher HF doses had 
survival superior to the patients in the AHF arms or 
lower HF doses.
The in silico experiments performed involve three 
hypothetical  imageable  GBM  tumours,  otherwise 
identical  except  for  their  radiosensitivity  param­
eters.  In  particular,  the  cases  considered  were  the 
following:
a.  A  GBM  tumour  with  intact  wild­type  (wt)  p53 
function,  and  accordingly  adjusted  LQ  Model 
parameters.35
αp = 0.61 Gy-1, βp = 0.02 Gy-2
b. A GBM tumour with mutant (mt) p53 gene35:
αp = 0.17 Gy-1, βp = 0.02 Gy-2
c.  A  GBM  tumour  with  intermediately  adjusted 
radiosensitivity:
αp = 0.36 Gy-1, βp = 0.02 Gy-2
In all cases, we set (Kocher;7 Perez and Brady,45 p. 99):
  αG0 = αp/OER, βG0 = βp/OER2, OER = 3  (19)
and
  αS = 0.6αp + 0.4αG0, βS = 0.6βp + 0.4βG0.  (20)
The  meaning  of  the  symbols  used  is  the 
following:
αP, βp: the LQ Model parameters for all prolifera­
tive cell cycle phases except for the DNA synthesis 
phase (S phase).
αS, βS: the LQ Model parameters for the S phase.
αG0, βG0: the LQ Model parameters for the resting 
G0 phase.Introduction of hypermatrix and operator notation into a discrete mathematics 
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The delivery of irradiation takes place at 08:00 
and 16:00 every day, 5 days per week (no irradiation 
during weekends). The distribution of the absorbed 
dose in the tumour region is assumed to be uniform. 
It should also be noted that carmustin, which was 
administered to all patients enrolled in the RTOG—
83-02 study, is assumed not to significantly modify 
the  relative  effectiveness  of  the  radiation  therapy 
schedules considered, as the chemotherapy adminis­
tration schedule was the same for all patients.
6.1. Construction of the hypermatrix
The first process that takes place before the appli­
cation  of  the  operators  is  the  discretization  of  the 
anatomic region of interest and the construction of 
the corresponding hypermatrix . The imaging data 
(e.g. T1 gadolinium enhanced MRI slices, PET slices 
etc.) including the definition of the tumour contour, 
its metabolically active sub­regions and the anato­
mical  structures  of  interest,  the  histopathological 
(e.g. type of tumour) and the genetic data (e.g. p53 
status and other molecular data) of the patient are 
collected.  The  clinician  delineates  the  tumour  and 
the anatomical structures of interest by using a dedi­
cated computer tool. In the case of radiotherapy, the 
planned distribution of the absorbed dose (e.g. in Gy) 
in the region of interest is also acquired. For the pur­
pose of the 3D reconstruction and visualization of 
both the initial tumour and the simulation outcome, 
the 3D visualization package AVS/ Express 4.2 has 
been used, (for details concerning the use of AVS/
Express in the simulation model refer to Stamatakos 
et al).18 The description of the biological activity of 
the tumour is implemented by introducing the notion 
of the ‘‘geometrical cell (GC)’’, the elementary cubic 
volume  of  the  3D  discretizing  mesh  covering  the 
region of interest as previously mentioned.
We assume that each GC of the mesh initially and 
normally accommodates a Number of Biological 
Cells (NBC). However, the maximum number of 
biological cells that is allowed to be accommodated 
within a GC is assumed to be NBC + [a fraction of 
NBC]. NBC apparently depends on the selected size 
of the GC and determines the quantization error of 
the model. The fraction of NBC considered in the 
code executions in this paper was 1/10 as this was 
shown to be the optimal one from both the con­
vergence and CPU time demands points of view.24 
Typical  clonogenic  cell  densities  are  104  to  105 
cells/mm3.4 Since most GBM tumours are poorly 
differentiated and rapidly growing, we assume a 
clonogenic cell density of 2 × 105 cells/mm3 in the 
proliferating cell region, 105 cells/mm3 in the G0 
cell region and 0.2 × 105 cells/mm3 in the dead cell 
region of the tumour.
It  is  noted  that  each  multidimensional  element 
of  the  proposed  hypermatrix  has  a  clear  physical 
and/or biological meaning (e.g. number of biologi­
cal cells within a given phase, number of therapy 
hit cells residing in a given phase etc.). Therefore, 
the hypermatrix (such as the exemplary one outlined 
above) is used to describe the distribution of several 
critical physical and biological quantities over space 
and time.
6.2. Operator based presentation  
of the simulation model basics
In the following the various processes constituting 
the entire simulation algorithm are briefly and sepa­
rately described with reference to the corresponding 
operators.
6.2.1. Operator f  T
Time is discretized and incremented. One hour has 
been adopted as the unit of time since 1h is the approxi­
mate duration of mitosis, the shortest cell cycle phase. 
According  to  the  prescribed  radiotherapy  scheme 
the  specific  instants  corresponding  to  the  delivery 
of a radiation dose to the tumour region are defined. 
In each time step the geometrical mesh is scanned and 
the updated state of a given GC is determined on the 
basis of a number of behaviour algorithms:
6.2.2. Operator f  O
During each scan of the discretization mesh the effect 
of  the  oxygen  and  nutrient  provision  on  the  cells 
of each geometrical cell is taken into account. This 
provision, determining the metabolic potential of a 
region, is based on the imaging data and determines 
the distribution of the tumour cells in the prolifera­
tive, dormant and necrotic states within the regions 
without taking into account the eventual therapeutic 
interventions effects. Furthermore, distribution of the 
cells over the cell cycle phases (G1, S, G2, Mitosis) 
is  considered  based  on  experimental  evidence 
(Katzung (Ed),37).stamatakos and Dionysiou
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6.2.3. Operator f  H
(I) At the time instants corresponding to the delivery of 
a specific radiation dose to the tumour (according to the 
prescribed radiotherapy scheme and the acquired distri­
bution of the absorbed dose in the region of interest) the 
number of cells killed in a particular GC is calculated 
based on the Linear Quadratic (LQ) Model, which is 
widely used in the pertinent literature.5,7,38,39 The fraction 
of cells surviving from a radiation dose D is given by
  S(D) = exp[–(αD + βD2)]  (21)
where α (Gy-1) and β (Gy-2) characterize the initial slope 
and the curvature, respectively, of the survival curve.
In an untreated tumour simulation case, the dose D 
would be set to zero.
(II) Lethally damaged cells following exposure to 
radiation undergo two mitotic divisions prior to death 
and disappearance from the tumour.39 
Note: Any eventual molecular perturbators of the 
cell surviving fraction are to be incorporated into this 
operator.
6.2.4. Operator f  C
At each time step the time registers of all GCs are 
incremented by one hour. Cell loss due to apoptosis 
and necrosis is computed. According to the cytokinetic 
model appearing in23 possible transitions of the cells 
within a GC include: G1→S (if time spent in the G1 cell 
cycle phase  TG1; TG1 = duration of the G1 phase), 
S→G2 (if time spent in the S cell cycle phase  TS; 
TS = duration of the S phase), G2→M (if time spent 
in the G2 cell cycle phase  TG2; TG2 = duration of 
the G2 phase), M→G1 or M→G0 (if time spent in the 
M cell cycle phase  TM; TM = duration of mitosis), 
G0→G1 (if adequate oxygen and nutrient provision 
has been re­established) or G0→N (if time spent in 
the G0 cell cycle phase  TG0; TG0 = maximum dura­
tion of the G0 phase before a cell enters necrosis). 
The previously mentioned durations of the cell cycle 
phases TX, X ∈{G1, S, G2, M, G0} seem to follow the 
normal distribution according to pertinent literature. 
As a first approximation, we use the mean values of 
the duration of each cell cycle phase and neglect stan­
dard  deviations.  However  pseudo­random  number 
generators are used in order to de­synchronize the 
equivalence classes throughout the tumour.
The cell cycle duration TC has been taken equal to 
40 h. This is the average of the cell cycle durations 
we have found in the literature for GBM cell lines.40,41 
In Katzung37 the approximate percentage of the cell 
cycle time spent in each phase by a typical malignant 
cell is assumed as follows: TG1 = 0.4TC, TS = 0.39TC, 
TG2 = 0.19TC, TM = 0.02TC. The duration of the G0 
phase is taken to be TG0=25 h.42
The cell loss factor (CLF) is considered equal to 
0.3.43 In 44 the authors note that cell loss is mainly due 
to necrosis (CLFN) and apoptosis (CLFA) and that 
gliomas have a low CLF in general. We assume that 
the total CLF (0.3) is the sum of the CLFN (0.27) and 
CLFA (0.03). We hypothesize low levels of apoptotic 
cells for GBM, as we have found that this is in general 
the case for gliomas.35,36,44
6.2.5. Operator f  E
The  differential  tumour  expansion  and  shrinkage 
algorithms are based on the use of random number 
generators in conjunction with adequately formed mor­
phological rules. These rules lead to tumour shrinkage 
or  expansion  conformal  to  the  initial  shape  of  the 
tumour (if the mechanical properties of the surround­
ing normal tissue are considered uniform around the 
tumour and the tumour is not in contact with practi­
cally undeformable tissues such as bone). Two versions 
of the expansion and shrinkage algorithms have been 
tested. First version (a): For each GC, one out of the 
six possible directions of shrinkage or expansion is 
randomly chosen (Cartesian coordinate system XYZ 
centered at the current GC. Each axis defines two pos­
sible  directions  of  movement).  Second  version  (b1) 
Shrinkage:  The  outermost  tumour  GC  is  detected 
along  each  one  of  the  six  possible  directions  of 
shrinkage (Cartesian coordinate system XYZ centered 
at  the  current  GC.  Each  axis  defines  two  possible 
directions  of  movement).  Its  ‘‘6­Neighbour’’  GCs 
belonging to the Tumour (NGCT) are counted. The 
direction  corresponding  to  the  maximum  NGCT  is 
finally selected out of the six possible directions as the 
direction along which the shifting of the GCs will take 
place (shifting direction). In case that more than one 
shifting directions have the same maximum NGCT, 
then the selection is based on the use of a random 
number  generator.  Second  version  (b2)  Expansion: 
A similar, though inverse, morphological—mechanical 
rule can be applied in the case of tumour expansion. The 
need for the formulation of the second improved version 
of the tumour shrinkage and expansion algorithm has Introduction of hypermatrix and operator notation into a discrete mathematics 
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arisen from the inspection of the macroscopic results of 
the simulation algorithms. Specifically, the completely 
random selection of one out of the six possible shift­
ing directions, according to the first version, results 
in a premature extensive fragmentation of the tumour 
region in case of radiotherapy, which is usually incom­
patible with clinical experience. The general trend is a 
conformal shrinking of most solid tumours (Perez and 
Brady,45 Figs. 1–4, p. 10). Using the second version of 
the algorithms this problem is solved. The mechanical 
properties of the surrounding normal tissue are consid­
ered uniform around the tumour, with the exception 
of an absolute lack of deformability of the bone. As a 
first approximation immunological reactions, invasion 
and formation of metastases have been ignored.
6.2.6. Operator f  U
After  having  completed  a  scan  of  the  discretizing 
mesh the oxygen and nutrient field is updated based 
on the criterion determining the relative position of 
the proliferative, dormant and necrotic regions of the 
tumour. The reason for this process is to take into 
account any eventual expansion or shrinkage of the 
tumour that would lead to a perturbation of the previ­
ous metabolic potential field.
7. Results
In order to clarify the actual effect of the composite 
discrete  operator  f  introduced  above  the  following 
indicative simulation predictions are included in this 
paper. Figures 3, 4 and 5 present the results of the 
in silico experiments in the form of the number of 
surviving  tumour  cells  (proliferating  and  dormant) 
as a function of time, for the tumours with mutant 
p53, wild­type p53 and the tumour with intermediate 
radiosensitivity,  correspondingly.  Improved  tumour 
control following high­dose HF irradiation is evident 
in the diagrams and is in agreement with the conclu­
sions of the clinical study RTOG 83­02. In fact, the 
higher the total dose in an HF schedule, the better the 
result in terms of tumour cell kill. It should be noted 
that the clinical study compared the treatments based 
on  patient  survival  whereas  the  simulation  results 
presented refer to tumour responsiveness. Although 
a  correspondence  of  patient  survival  with  tumour 
responsiveness  may  not  always  hold  on  a  single 
patient  basis,  when  taking  into  account  relatively 
large clinical trial populations such a correspondence 
becomes much more reasonable.
More specifically, the inspection of the simulation 
results reveals that AHF schedules, which employ 
a  higher  fraction  dose  compared  to  HF  sched­
ules, seem at first to be beneficial as they achieve 
the  maximum  tumour  cell  kill  at  some  instant. 
Nevertheless, the duration of the AHF schedules is 
smaller; as a result, if they fail in eradicating “all” 
tumour  cells,  tumour  repopulation  begins  earlier 
(as in the cases of the tumour with mt p53 and the 
tumour with intermediate radiosensitivity). Only in 
the case of the tumour with wt p53, do all radio­
therapy  schemes  kill  all  the  clonogenic  cells  we 
have initially assumed (although this may not be the 
case in reality due to considerable instabilities of 
the simulation when it comes to the last few living 
tumour  cells  (chaotic  behaviour  limits)),  so  the 
tumour does not regrow after the end of the treat­
ment. Of course, regions of potential microscopic 
disease have not been considered, and the accuracy 
of the simulation model decreases as the number of 
tumour cells is reduced.
8. Discussion
The introduction of operator notation into the pro­
cess  of  modeling  malignant  tumour  response  to 
therapeutic schemes has led to a brief and compre­
hensive description of the major steps of the simula­
tion process. In this way highly complex algorithmic 
ECOSYSTEM LEVEL
POPULATION LEVEL
ORGANISM LEVEL
SYSTEM LEVEL
ORGAN LEVEL
TISSUE LEVEL
CELLULAR LEVEL
SUBCELLULAR LEVEL
MOLECULAR LEVEL
ATOMIC LEVEL
Figure 2. The proposed ten levels of biocomplexity.stamatakos and Dionysiou
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treatments are decomposed into simpler procedures 
which are readily identifiable by the wider research 
community.  The  use  of  mathematical  symbols  to 
denote  complex  algorithmic  processes  is  expected 
to  function  as  a  stimulant  for  the  advancement  of 
multilevel  biological  modeling  through  symbolic 
mathematical  expressions.  Such  expressions  could 
by  themselves  provide  hints  for  further  questions, 
investigations and optimizations due to their inherent 
logical and quantitative associations. Especially the 
analogy of the operator notation in biomedicine with 
their use in several fields of physics such as classical 
and quantum mechanics can act as a source of guid­
ance and quantitative insight into the hypercomplex 
biological phenomena.
Obviously the treatment presented should be viewed 
only as an initial step of a rather long term modeling 
process as more and more experimental and clinical 
knowledge could be incorporated into the models which 
are under continuous development and optimization. 
Specific  aspects  that  are  currently  addressed  in 
parallel include i.a. the mitotic potential categories 
of  the  cancer  stem,  progenitor  and  differentiated 
cells  (leading  to  a  new  dimension  in  the  discrete 
abstract space),28,29 adjacent normal tissue response,46 
molecular  networks  (adapting  the  cell  survival 
probability  to  the  patient  individualized  context), 
chemotherapy  optimization20,21,28,29  etc.  A  possible 
application of the approach presented in this paper 
is  on  the  development  of  the  in  silico  oncology 
action  of  the  European  Commission  (EC)  funded 
project  “ACGT:  Advancing  Clinicogenomic  Trials 
on  Cancer”  (FP6­2005­IST­026996).  In  particular 
the  development  of  the  software  simulation  tool 
named  “Oncosimulator”47  can  be  described  based 
on the notation proposed in this paper. An analogous 
simulation  tool  is  being  developed  within  the 
framework of the EC funded project “ContraCancrum: 
Clinically Oriented Translational Cancer Multilevel 
Modelling” (FP7­ICT­2007­2­223979).
9. conclusions
The  introduction  of  the  proposed  hypermatrix  and 
operator notation in order to denote, decompose and 
identify  complex  biological  mechanisms  that  con­
tribute to the hypercomplex phenomenon of malig­
nant  tumour  growth  and  response  to  therapeutic 
schemes  has  been  presented  through  the  use  of  a 
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Figure 5. number of surviving tumour cells as a function of time for the glioblastoma tumour with intermediately adjusted radiosensitivity parameters (see 
section 6). The radiotherapeutic schemes correspond to schemes considered by the rTOg 83-02 clinical study.
Abbreviations: AhF, accelerated hyperfractionation; hF, hyperfractionation. 
discrete  mathematics  simulation  model  concerning 
radiotherapy response. Several aspects of the model 
had  been  developed  by  our  research  group  in  the 
past. Symbolic operator notation has provided a com­
pact way of describing the most crucial simulation 
steps thus offering a possible basis for quantitative 
multilevel  biology  based  on  discrete  mathematics. 
Furthermore, simulation results mimicking branches 
of the RTOG 83­02 clinical study have provided both 
clarification of the actual content of the composite 
discrete  operator  and  additional  evidence  for  the 
potential of the simulation approach presented.stamatakos and Dionysiou
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